Open AccessDidymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor Protein
Author(s) -
Xing Lin,
Faicheng Bai,
Jinlan Nie,
Shengjuan Lu,
Chunyuang Lu,
Xunshuai Zhu,
Jinbin Wei,
Zhongpeng Lu,
Quanfang Huang
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000453194
Subject(s) - protein kinase b , pi3k/akt/mtor pathway , mapk/erk pathway , protein kinase a , cancer research , kinase , microbiology and biotechnology , fibrosis , signal transduction , p38 mitogen activated protein kinases , chemistry , hepatic fibrosis , pharmacology , medicine , biology
Didymin has been reported to have anti-cancer potential. However, the effect of didymin on liver fibrosis remains illdefined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom